Evaluating the impact of pneumococcal vaccination on invasive infections in children

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the effects of the 7 and 13 valent pneumococcal conjugate vaccines implemented in France on invasive pneumococcal disease (IPD) in children. It will involve the collection and analysis of clinical data related to IPD cases, including serotyping of the pneumococcus, underlying health conditions, and vaccination status of the affected individuals. The study will utilize isolates from various sterile body sites to understand the epidemiology of IPD post-vaccination.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Isolate of Streptococcus pneumoniae from at least one blood culture, or pleural fluid, or joint fluid, or cerebrospinal fluid or other normally sterile body site, or if there is a positive blood polymerase chain reaction (PCR).

Exclusion Criteria:

* Pneumococcal strain not transmetted to National Reference Center for Pneumococci or to Regional Pneumococci Observatory

Where it's running

• Activ
  Créteil, France Recruiting

Study contacts

• Principal investigator: Cohen Robert — Association Clinique Thérapeutique Infantile du val de Marne
• Study coordinator: Levy Corinne
• Email: corinne.levy@activ-france.fr
• Phone: 1 48 85 04 04

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• National survey on bacterial meningitis in children

  This study is trying to learn more about bacterial meningitis in children by looking at which bacteria are causing it and how things have changed since the introduction of vaccines.

  Recruiting Association Clinique Thérapeutique Infantile du val de Marne · Créteil · NCT04664569

• Bloom Infant Probiotic: Can a probiotic help vaccines work better after early antibiotics?

  We’re testing if giving Infloran probiotic to newborns who had antibiotics in the first 28 days helps their vaccines produce stronger antibodies.

  Recruiting Phase 2 South Australian Health and Medical Research Institute · Adelaide, South Australia and 1 other locations · NCT07189390

• Nasal immune responses in older adults with pneumococcal or viral respiratory infections

  This project will test whether nasal immune responses differ in adults 60–85 with pneumococcal pneumonia, older adults carrying pneumococcus without symptoms, and those with flu or RSV.

  Recruiting University Hospital, Geneva · Geneva · NCT06998251

• PCV-20 vaccination for adults during a short febrile illness

  This test sees if giving the PCV-20 pneumococcal vaccine to adults hospitalized with a short, non-severe fever produces the same immune response and safety as giving it after the fever has resolved.

  Recruiting Phase 4 Centre Hospitalier Universitaire de Saint Etienne · Saint-Etienne, France and 23 other locations · NCT06822907

• Restoring gut health in infants after antibiotic use with fecal transplants

  This study is testing whether giving healthy poop from the same child back to infants and toddlers who have taken antibiotics can help restore their gut health.

  Recruiting Phase 1 Rutgers, The State University of New Jersey · New Brunswick, New Jersey · NCT06609980

• Evaluating a new pneumococcal vaccine in infants

  This study is testing a new pneumococcal vaccine for infants to see if it is safe and works as well as an existing vaccine when given with other routine shots.

  Recruiting Phase 3 Beijing Minhai Biotechnology Co., Ltd · Denpasar, Bali and 2 other locations · NCT06608199

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.